公开(公告)号：US12128103B2

公开(公告)日：2024-10-29

申请号：US18637283

申请日：2024-04-16

Applicant: Genentech, Inc. ,  Hoffmann-La Roche Inc.

Inventor： Mark C. Benyunes ,  Graham Alexander Ross

IPC: A61K39/395 ,  A61K9/00 ,  A61K31/337 ,  A61K45/06 ,  A61P35/00 ,  C07K16/32 ,  A61K39/00

CPC classification number: A61K39/39558 ,  A61K9/0019 ,  A61K45/06 ,  A61P35/00 ,  C07K16/32 ,  A61K31/337 ,  A61K2039/507 ,  A61K2039/545 ,  A61K2300/00

Abstract: Methods are provided for the adjuvant treatment of operable HER2-positive primary breast cancer in human patients by administration of pertuzumab in addition to chemotherapy and trastuzumab. The methods reduce the risk of recurrence of invasive breast cancer or death for a patient diagnosed with HER2-positive early breast cancer (eBC) compared to administration of trastuzumab and chemotherapy, without pertuzumab.

公开(公告)号：US11077189B2

公开(公告)日：2021-08-03

申请号：US15907718

申请日：2018-02-28

Applicant: Genentech, Inc. ,  F. Hoffmann-La Roche AG

Inventor： Mark C. Benyunes ,  Graham Alexander Ross

IPC: A61K39/395 ,  C07K16/32 ,  A61K9/00 ,  A61K45/06 ,  A61P35/00 ,  A61K39/00

Abstract: Methods are provided for the adjuvant treatment of operable HER2-positive primary breast cancer in human patients by administration of pertuzumab in addition to chemotherapy and trastuzumab. The methods reduce the risk of recurrence of invasive breast cancer or death for a patient diagnosed with HER2-positive early breast cancer (eBC) compared to administration of trastuzumab and chemotherapy, without pertuzumab.

公开(公告)号：US20250018032A1

公开(公告)日：2025-01-16

申请号：US18893603

申请日：2024-09-23

Applicant: Genentech, Inc. ,  Hoffmann-La Roche Inc.

Inventor： Mark C. Benyunes ,  Graham Alexander Ross

IPC: A61K39/395 ,  A61K9/00 ,  A61K31/337 ,  A61K39/00 ,  A61K45/06 ,  A61P35/00 ,  C07K16/32

Abstract: Methods are provided for the adjuvant treatment of operable HER2-positive primary breast cancer in human patients by administration of pertuzumab in addition to chemotherapy and trastuzumab. The methods reduce the risk of recurrence of invasive breast cancer or death for a patient diagnosed with HER2-positive early breast cancer (eBC) compared to administration of trastuzumab and chemotherapy, without pertuzumab.

公开(公告)号：US20210015919A1

公开(公告)日：2021-01-21

申请号：US16992966

申请日：2020-08-13

Applicant: Genentech, Inc.

Inventor： Mark C. Benyunes ,  Emma L. Clark ,  Graham A. Ross

IPC: A61K39/395 ,  A61K45/06 ,  C07K16/32 ,  A61K31/337

Abstract: The present application describes uses for Pertuzumab, a first-in-class HER2 dimerization inhibitor. In particular, the application describes methods for extending progression free survival in a HER2-positive breast cancer patient population; and combining two HER2 antibodies to treat HER2-positive cancer without increasing cardiac toxicity.

公开(公告)号：US20190117769A1

公开(公告)日：2019-04-25

申请号：US16123809

申请日：2018-09-06

Applicant: Genentech, Inc.

Inventor： Mark C. Benyunes ,  Emma L. Clark ,  Lada Mitchell ,  Christina H. de Toledo Pelizon ,  Jayantha Ratnayake ,  Graham A. Ross

IPC: A61K39/395 ,  C07K16/32 ,  A61K31/337 ,  A61K45/06

Abstract: The present application describes uses for Pertuzumab, a first-in-class HER2 dimerization inhibitor. In particular, the application describes methods for extending progression free survival in a HER2-positive breast cancer patient population; and combining two HER2 antibodies to treat HER2-positive cancer without increasing cardiac toxicity.

公开(公告)号：US20160175438A1

公开(公告)日：2016-06-23

申请号：US15058520

申请日：2016-03-02

Applicant: Genentech, Inc.

Inventor： Sreedhara Alavattam ,  Lukas C. Amler ,  Mark C. Benyunes ,  Emma L. Clark ,  Christina H. de Toledo Pelizon ,  Zephania W. Kwong Glover ,  Lada Mitchell ,  Jayantha Ratnayake ,  Graham A. Ross ,  Ru-Amir Walker

IPC: A61K39/395 ,  A61K31/337 ,  A61K45/06 ,  C07K16/32

CPC classification number: A61K39/39558 ,  A61K31/337 ,  A61K45/06 ,  A61K2039/507 ,  A61K2039/545 ,  C07K16/32 ,  C07K2317/24 ,  A61K2300/00

Abstract: The present application describes uses for Pertuzumab, a first-in-class HER2 dimerization inhibitor. In particular, the application describes methods for extending progression free survival in a HER2-positive breast cancer patient population; combining two HER2 antibodies to treat HER2-positive cancer without increasing cardiac toxicity; and treating HER2-positive cancer by co-administering a mixture of Pertuzumab and Trastuzumab from the same intravenous bag.

Abstract translation: 本申请描述了一种同类别的HER2二聚抑制剂Pertuzumab的用途。 特别地，本申请描述了在HER2阳性乳腺癌患者群体中扩展无进展生存的方法; 结合两种HER2抗体治疗HER2阳性癌症而不增加心脏毒性; 并通过从相同的静脉内袋中共同施用Pertuzumab和曲妥珠单抗的混合物来治疗HER2阳性癌症。

公开(公告)号：US20240252634A1

公开(公告)日：2024-08-01

申请号：US18637283

申请日：2024-04-16

Applicant: Genentech, Inc. ,  Hoffmann-La Roche Inc.

Inventor： Mark C. Benyunes ,  Graham Alexander Ross

IPC: A61K39/395 ,  A61K9/00 ,  A61K31/337 ,  A61K39/00 ,  A61K45/06 ,  A61P35/00 ,  C07K16/32

CPC classification number: A61K39/39558 ,  A61K9/0019 ,  A61K45/06 ,  A61P35/00 ,  C07K16/32 ,  A61K31/337 ,  A61K2039/507 ,  A61K2039/545 ,  A61K2300/00

Abstract: Methods are provided for the adjuvant treatment of operable HER2-positive primary breast cancer in human patients by administration of pertuzumab in addition to chemotherapy and trastuzumab. The methods reduce the risk of recurrence of invasive breast cancer or death for a patient diagnosed with HER2-positive early breast cancer (eBC) compared to administration of trastuzumab and chemotherapy, without pertuzumab.

公开(公告)号：US11992529B2

公开(公告)日：2024-05-28

申请号：US17305556

申请日：2021-07-09

Applicant: Genentech, Inc. ,  Hoffmann-La Roche Inc.

Inventor： Mark C. Benyunes ,  Graham Alexander Ross

IPC: A61K39/395 ,  A61K9/00 ,  A61K45/06 ,  A61P35/00 ,  C07K16/32 ,  A61K31/337 ,  A61K39/00

CPC classification number: A61K39/39558 ,  A61K9/0019 ,  A61K45/06 ,  A61P35/00 ,  C07K16/32 ,  A61K31/337 ,  A61K2039/507 ,  A61K2039/545 ,  A61K2300/00

Abstract: Methods are provided for the adjuvant treatment of operable HER2-positive primary breast cancer in human patients by administration of pertuzumab in addition to chemotherapy and trastuzumab. The methods reduce the risk of recurrence of invasive breast cancer or death for a patient diagnosed with HER2-positive early breast cancer (eBC) compared to administration of trastuzumab and chemotherapy, without pertuzumab.

公开(公告)号：US20220362379A1

公开(公告)日：2022-11-17

申请号：US17656732

申请日：2022-03-28

Applicant: Genentech, Inc.

Inventor： Mark C. Benyunes ,  Emma L. Clark ,  Jayantha Ratnayake ,  Graham A. Ross

IPC: A61K39/395 ,  A61K45/06 ,  C07K16/32 ,  A61K31/337

Abstract: The present application describes uses for Pertuzumab, a first-in-class HER2 dimerization inhibitor. In particular, the application describes methods for extending progression free survival in a HER2-positive breast cancer patient population; and combining two HER2 antibodies to treat HER2-positive cancer without increasing cardiac toxicity.

公开(公告)号：US11638756B2

公开(公告)日：2023-05-02

申请号：US17821270

申请日：2022-08-22

Applicant: Genentech, Inc. ,  Hoffmann-La Roche Inc.

Inventor： Mark C. Benyunes ,  Graham Alexander Ross

IPC: A61K39/395 ,  C07K16/32 ,  A61P35/00 ,  A61K31/337 ,  A61K9/00 ,  A61K45/06 ,  A61K39/00

Abstract: Methods are provided for the adjuvant treatment of operable HER2-positive primary breast cancer in human patients by administration of pertuzumab in addition to chemotherapy and trastuzumab. The methods reduce the risk of recurrence of invasive breast cancer or death for a patient diagnosed with HER2-positive early breast cancer (eBC) compared to administration of trastuzumab and chemotherapy, without pertuzumab.